Addex Therapeutics (ADXN) Set to Announce Quarterly Earnings on Monday

Addex Therapeutics (NASDAQ:ADXN) is scheduled to issue its quarterly earnings data before the market opens on Monday, November 11th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter.

Addex Therapeutics (NASDAQ:ADXN) last announced its quarterly earnings results on Monday, September 30th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). Addex Therapeutics had a net margin of 463.11% and a negative return on equity of 190.29%. The business had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.26 million. On average, analysts expect Addex Therapeutics to post $10 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Addex Therapeutics Trading Down 0.8 %

ADXN opened at $10.55 on Friday. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90. The company has a market cap of $11.18 million, a price-to-earnings ratio of -6.49 and a beta of 1.78. The company’s fifty day moving average price is $10.36 and its two-hundred day moving average price is $9.37.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Addex Therapeutics in a research report on Wednesday, October 2nd.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.